Phase I study of novel gene therapy for HIV
A Phase I study of novel gene therapy VRX496 for HIV treatment found five patients experienced decreases in viral load and stable or increased CD4 T cell counts after receiving the treatment. The trial also demonstrated the treatment's potential to restore normal immune function against other infections.